BICO Group AB (publ) (BCCOY)
BICO Group AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Gothenburg, VG, SE. The stock last traded at $0.37, up 0.00% on the session, giving a market capitalisation of $104.1M. On trailing twelve-month figures it carries a trailing P/E of -1.19, a net margin of -66.1%. Its beta of 2.54 implies it has historically moved more than the broad market.
BICO Group AB (publ), originally founded in 2016 as Cellink AB (publ) in Gothenburg, Sweden, and subsequently renamed in August 2021, functions as a bio-convergence leader. The company extends its operations internationally, with a presence spanning North America, Europe, and Asia. Its business is structured into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions segment provides sophisticated scientific equipment, including 3D bioprinters, hybrid microscopes, single-cell dispensing devices, and liquid handling instruments. This division also supplies critical consumables such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues, particularly those utilized in regulatory testing. Furthermore, it offers specialized services in areas like 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology, primarily serving pharmaceutical and biotechnology enterprises. In contrast, the Bioautomation segment delivers precision dispensing and biosensor technologies to industrial customers. It also provides advanced robotics and diagnostics automation solutions tailored for the medical and diagnostic sectors. Beyond these, this segment develops comprehensive solutions encompassing core industrial ecosystems, tissue engineering, multi-omics, cell line development, and diagnostics. Its main clientele comprises the medical, pharmaceutical, and cosmetic industries.
BICO Group AB (publ) is most often compared with the following Healthcare names: